Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Non Operating Income: 2019-2024

Historic Non Operating Income for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $14.4 million.

  • C4 Therapeutics' Non Operating Income fell 37.23% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 23.21%. This contributed to the annual value of $14.4 million for FY2024, which is 84.56% up from last year.
  • Latest data reveals that C4 Therapeutics reported Non Operating Income of $14.4 million as of FY2024, which was up 84.56% from $7.8 million recorded in FY2023.
  • Over the past 5 years, C4 Therapeutics' Non Operating Income peaked at $14.4 million during FY2024, and registered a low of -$6.5 million during FY2020.
  • Moreover, its 3-year median value for Non Operating Income was $7.8 million (2023), whereas its average is $7.9 million.
  • In the last 5 years, C4 Therapeutics' Non Operating Income crashed by 401.90% in 2020 and then soared by 475.28% in 2023.
  • Over the past 5 years, C4 Therapeutics' Non Operating Income (Yearly) stood at -$6.5 million in 2020, then skyrocketed by 73.00% to -$1.8 million in 2021, then soared by 177.30% to $1.4 million in 2022, then spiked by 475.28% to $7.8 million in 2023, then surged by 84.56% to $14.4 million in 2024.